Form 4: CEO Jordan Acquires 771K ATNF Stock Options

180 Life Sciences CEO Blair Jordan acquired 771,044 non-qualified stock options and holds significant voting control over additional common shares through various agreements.

Summary

• Chief Executive Officer Blair Jordan of 180 Life Sciences Corp. acquired 771,044 non-qualified stock options on August 8, 2025.
• The options have an exercise price of $3.01 and are set to expire on August 8, 2035.
• These options vested immediately but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received.
• If stockholder approval is not obtained by August 8, 2026, the options will be cancelled.
• The options were issued to Mr. Jordan in consideration for services rendered and agreed to be rendered as an officer of the Issuer.
• Mr. Jordan is also deemed to beneficially own 43,166 shares of common stock held by Dr. James Woody, 200,000 shares held by Dr. Marlene Krauss, and 1,318,000 shares held by Elray Resources, Inc. due to irrevocable voting proxies.
• These voting proxies grant Mr. Jordan limited voting rights as recommended by the Board of Directors, but he has no dispositive control or pecuniary interest in these shares.

Sentiment

Score: 6

Explanation: The acquisition of options aligns management incentives with shareholder value, which is positive. However, the contingency on stockholder approval for exercisability introduces a minor uncertainty. The voting agreements are a governance mechanism, neither inherently positive nor negative without further context on their impact.

Positives

• The acquisition of 771,044 stock options aligns the CEO's long-term financial interests with those of the shareholders, incentivizing value creation.
• The options were granted as compensation for services, which is a standard practice for executive remuneration.
• The voting agreements consolidate voting power for shares, ensuring they are voted as recommended by the Board of Directors, which can contribute to governance stability.

Negatives

• The exercisability of the 771,044 stock options is contingent on future stockholder approval of the 2025 Second Supplemental Option Plan, introducing a degree of uncertainty.
• There is a risk that the options will be cancelled if stockholder approval is not secured by August 8, 2026.
• The deemed beneficial ownership through voting proxies does not confer direct economic interest or dispositive control over the underlying shares, limiting the CEO's direct financial stake in those specific holdings.

Risks

• The 771,044 non-qualified stock options granted to the CEO will be cancelled if stockholder approval of the 2025 Second Supplemental Option Plan is not received prior to August 8, 2026.
• The voting agreements with Dr. James Woody, Dr. Marlene Krauss, and Elray Resources, Inc. are time-limited, expiring on specific future dates, which could lead to changes in voting control over those shares.

Future Outlook

The exercisability of 771,044 stock options is contingent on future stockholder approval of the 2025 Second Supplemental Option Plan, which must be obtained by August 8, 2026, or the options will be cancelled. Additionally, the various voting agreements granting deemed beneficial ownership are set to expire on specific future dates, potentially altering voting control.

Management Comments

• The non-qualified stock options were issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer.

Industry Context

This filing is a standard insider transaction report (Form 4) common across all industries, detailing executive compensation and beneficial ownership. For 180 Life Sciences Corp., a life sciences company, the specific details relate to how executive incentives are structured and how corporate governance, particularly voting control, is managed through agreements with key shareholders.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of stock options; increased alignment of the CEO's interests with shareholder value; consolidated voting power for board recommendations through voting agreements.

Next Steps

• Stockholder approval of the 2025 Second Supplemental Option Plan is required for the 771,044 options to become exercisable.
• The various voting agreements will expire on their respective dates (August 21, 2025; February 5, 2026; April 28, 2026), potentially leading to changes in voting control.

Key Dates

Keywords

180 Life Sciences Corp, ATNF, Blair Jordan, Stock Options, Beneficial Ownership, SEC Form 4, Insider Trading, Corporate Governance, Voting Agreement, Executive Compensation